← Back
Data updated: Sep 20, 2026
ATLAS PHARMS LLC
Generics Pharmaceuticals
ATLAS PHARMS LLC is a generic drug manufacturer with 1 FDA-approved products.
2016
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
ATLAS PHARMS LLC's Key Drugs
ATLAS PHARMS LLC's core commercial portfolio centers on IRBESARTAN AND HYDROCHLOROTHIAZIDE — its most strategically important drugs approved in the last 15 years.
ATLAS PHARMS LLC's Recent FDA Approvals
New NDA/BLA approvals for ATLAS PHARMS LLC over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
ATLAS PHARMS LLC's Therapeutic Areas
Disease areas where ATLAS PHARMS LLC has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
ATLAS PHARMS LLC Pipeline Snapshot
Active clinical trials for ATLAS PHARMS LLC across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • IRBESARTAN AND HYDROCHLOROTHIAZIDE leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2016-01-15
- Latest
- 2016-01-15
- Applications
- 1